Clinical Trial Search

Primary: Percentage of Participants Who Achieved Success Rate 0 (Clear) or 1 (Almost Clear) on the Investigator Global Assessment (IGA) Scale at Week 12 (Last Observation Carried…

Primary: Number of Participants With Daytime Cough Resolution Rate by Day 8 in the PP Population — 67; 64; 21; 27 Participants

Primary: Percentage of Participants With ≥1 Solicited Injection-site Adverse Events — 54.4; 57.9; 50.9; 59.6 Percentage of Participants

Primary: AUC0-6h of Pain Intensity Between Time 0 (Baseline Value of VAS) and 6 Hours Post-treatment in the ITT Population. — 5031; 7593 mm*min — p=0.020

Primary: Percentage of Subjects With Treatment-emergent Adverse Events (TEAEs), Percentage of Subjects With Serious Adverse Events (SAEs), and Percentage of Subjects With…

Primary: Fraction of Approached Patients Who Enroll and Are Randomized — 1; 31 Participants

Primary: Global Cohort: Overall Survival (OS) — 9.8; 9.3 Months — p=0.0379

Primary: Time To Extubation — 46.9; 48.0 hours — p=<.05

Primary: Rett Syndrome Behaviour Questionnaire (RSBQ) Total Score - Change From Baseline to Week 12 — -4.9; -1.7 score on a scale — p=0.0175

Primary: Grade 3+ Adverse Events Rate — .032; .115 events per participant

Primary: Percentage of Participants Showing a Vaccine Response for Anti-glycoprotein E (gE) — 85.7; 7.8 Percentage of participants

Primary: Percent Change From Baseline in Body Weight — -3.3; -13.4; -15.7 percent change — p=<0.001

Primary: Pain Level — 3.4; 3.7; 2.8; 2.9 score on a scale

Primary: Duration of the Last Interval With no Disease Activity up to Week 56 - Study Eye — 68; 59; 47; 49 Participants

Primary: Percentage of Participants With Adverse Events (AEs) — 900 Participants